Clinical Trials Sponsored by Yunnan Institute

Total 75068 results

Hunan Cancer Hospital

Completed

Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer (ACTDNAGLT)

Metastatic Breast Cancer | Circulating Tumor DNA | Gene Abnormality
Hunan Normal University

Completed

Attention Bias Modification Treatment for Young Adults With Major Depressive Disorder

Depressive Disorder, Major

China
Hunan Cancer Hospital

Unknown

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Ovarian Cancer

China
University of Guelph
Alison Duncan

Completed

Effects of Omega-3 Fatty Acids on Risk Factors for Breast Cancer in Pre-menopausal Women

Healthy | Premenopausal Period
Chen Wannan

Unknown

Post Operative Pain Control of POEM Procedure

Achalasia
Kathleen Dungan

Completed

Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes

Type 2 Diabetes | Inpatient

United States
Dr Kundan Singh Chufal

Active, not recruiting

Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning (QARC)

Esophageal Neoplasm

Australia, India
M.D. Anderson Cancer Center
Duncan Family Institute (DFI) Seed Funding Program

Recruiting

Harmony & Health: Feasibility of a Movement Intervention to Improve Psychosocial Wellbeing in Black Adults in Northeast Texas

Psychological

United States
Shanghai Jiao Tong University School of Medicine
YUNNAN BAIYAO GROUP CO.,LTD

Completed

Study of Oral High/Low-dose Cepharanthine Compared With Placebo in Non Hospitalized Adults With COVID-19

Asymptomatic COVID-19

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
Shanghai Public Health Clinical Center
Yunnan AIDS Care Center; Xixi Hospital of Hangzhou

Active, not recruiting

Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

HIV-1-infection

China
LongStar HealthPro, Inc. DBA Farlong Pharmaceutical
KGK Science Inc.; Yunnan PanLongYunHai Pharmaceuticals, Ltd.

Completed

The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure

Hypertension | Hyperlipidemias
Yanyan Liu

Recruiting

Linperlisib Combined With Chidamide in Patients With PTCL

Peripheral T-cell Lymphoma

China
yue junhan

Recruiting

Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer (FOBECAMS)

Colorectal Cancer

China
Kathleen Dungan

Terminated

Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

Hyperglycemia | Diabetes Mellitus, Type 2

United States
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC (Apple)

Efficacy
Hunan Province Tumor Hospital

Recruiting

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Advanced Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

NSCLC

China
Hunan Province Tumor Hospital

Recruiting

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC (PACIFIC15)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

Lung Adenocarcinoma | ALK Gene Mutation | Immunotherapy

China
Hunan Province Tumor Hospital

Recruiting

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Small-cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial (POSEIDON)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

NSCLC

China
Hunan Province Tumor Hospital

Completed

To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers

Carcinoma, Non-small Cell Lung

China
Hunan Province Tumor Hospital

Completed

Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (SUCCESS)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Severe Adverse Events Biomarkers Investigation on Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type (Esporta)

Uncommon Pathological Types of Lung Cancer

China
Yuhan Corporation
Metro Hospital

Completed

Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg

Healthy Volunteers

Korea, Republic of
Yuhan Corporation
Linical Korea

Completed

A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia

Diabetes Mellitus and Hypercholesterolemia

Korea, Republic of
Yuhan Corporation
Linical Korea

Terminated

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

Metabolic Syndrome

Korea, Republic of
Hunan Province Tumor Hospital

Completed

Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

China
Hunan Province Tumor Hospital

Recruiting

Efficacy of Osimertinib in Patients With Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

Advanced Solid Tumors or Lymphomas

China
Hunan Province Tumor Hospital

Recruiting

Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer

Extensive-stage Small-cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

NSCLC

China
Hunan Province Tumor Hospital

Recruiting

Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma (FLYFLY)

Non-Small Cell Lung Cancer

China
Hunan Provincial People's Hospital

Recruiting

Temporary Transvenous Pacemaker Placement by Intracavitary Electrocardiogram Monitoring

Tachyarrhythmia | Brady-tachy Syndrome | Bradyarrhythmia | Bradycardia; Syncope | AVB - Atrioventricular Block | Tachycardia Bradycardia

China

3

Subscribe